Columbia Asset Management Has $8.47 Million Stock Position in Johnson & Johnson $JNJ

Columbia Asset Management reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 46.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,430 shares of the company’s stock after selling 49,000 shares during the quarter. Johnson & Johnson accounts for 1.7% of Columbia Asset Management’s holdings, making the stock its 12th biggest holding. Columbia Asset Management’s holdings in Johnson & Johnson were worth $8,467,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. PBMares Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. PBMares Wealth Management LLC now owns 8,445 shares of the company’s stock worth $1,290,000 after purchasing an additional 111 shares in the last quarter. Broadway Wealth Solutions Inc. grew its holdings in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Broadway Wealth Solutions Inc. now owns 2,917 shares of the company’s stock worth $446,000 after purchasing an additional 103 shares in the last quarter. Westhampton Capital LLC grew its position in Johnson & Johnson by 6.3% in the second quarter. Westhampton Capital LLC now owns 12,796 shares of the company’s stock valued at $1,955,000 after acquiring an additional 760 shares during the last quarter. Pennsylvania Capital Management Inc. ADV grew its position in Johnson & Johnson by 1,024.9% in the second quarter. Pennsylvania Capital Management Inc. ADV now owns 42,847 shares of the company’s stock valued at $6,545,000 after acquiring an additional 39,038 shares during the last quarter. Finally, Union Bancaire Privee UBP SA grew its position in Johnson & Johnson by 2.2% in the second quarter. Union Bancaire Privee UBP SA now owns 160,521 shares of the company’s stock valued at $24,520,000 after acquiring an additional 3,514 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $185.99 on Thursday. The business’s 50-day moving average price is $175.45 and its 200-day moving average price is $162.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $186.56. The firm has a market capitalization of $447.92 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, The Goldman Sachs Group lifted their price target on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.40.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.